FDA Approves Vyalev for Advanced Parkinson Disease

FDA Approves Vyalev (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease

drugs.com - 17/Oct 21:10

NORTH CHICAGO, Ill., Oct. 17, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved...

FDA Approves Itovebi for Locally Advanced, Metastatic Breast Cancer

drugs.com - 16/Oct 15:10

WEDNESDAY, Oct. 16, 2024 -- The U.S. Food and Drug Administration approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and...

FDA Approves Vyloy for Advanced Gastric or Gastroesophageal Junction Cancer

drugs.com - 23/Oct 14:10

WEDNESDAY, Oct. 23, 2024 -- The U.S. Food and Drug Administration has approved Vyloy (zolbetuximab-clzb) in combination with fluoropyrimidine- and...

U.S. FDA Approves Pfizer’s RSV Vaccine Abrysvo for Adults Aged 18 to 59 at Increased Risk for Disease

drugs.com - 22/Oct 05:10

NEW YORK--(BUSINESS WIRE) October 22, 2024 -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved...

FDA Approves Vyloy (zolbetuximab-clzb) for the Treatment of Advanced Gastric and GEJ Cancer

drugs.com - 21/Oct 01:10

TOKYO, Oct. 18, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food...

FDA Approves Hympavzi for Hemophilia

drugs.com - 15/Oct 16:01

TUESDAY, Oct. 15, 2024 -- The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or...

FDA Approves Orlynvah (sulopenem etzadroxil and probenecid) for the Treatment of Uncomplicated Urinary Tract Infections

drugs.com - 25/Oct 21:10

DUBLIN and CHICAGO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), today announced that the U.S. Food and Drug...

VYALEV (foscarbidopa/foslevodopa) injection [AbbVie Inc.]

nlm.nih.gov - 24/Oct 04:00

Updated Date: Thu, 24 Oct 2024 00:00:00 EDT

FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

drugs.com - 24/Oct 23:10

SEATTLE--(BUSINESS WIRE)--Oct. 24, 2024-- Omeros Corporation today announced that zaltenibart (OMS906) has received rare pediatric disease designation...

FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for Now

drugs.com - 15/Oct 12:33

TUESDAY, Oct. 15, 2024 -- Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug...

Rubriques :